Boston Scientific (BMV:BSX *) - 주가, 뉴스 및 분석

BSX * 주식 개요

Boston Scientific Corporation은 전 세계의 다양한 중재 의료 전문 분야에서 사용되는 의료 기기를 개발, 제조 및 판매합니다. 자세한 내용

BSX * 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	4/6
과거 실적	4/6
재무 상태	5/6
배당금	0/6

보상

수익은 매년 23.21% 증가할 것으로 예상됩니다.

지난 1년간 수익이 50.5% 증가했습니다.

위험 분석

주식은 유동성이 매우 낮습니다

Boston Scientific Corporation 경쟁사

Stryker

NYSE:SYK

US$148.2b

Medtronic

NYSE:MDT

US$109.0b

Intuitive Surgical

NasdaqGS:ISRG

US$191.9b

Abbott Laboratories

NYSE:ABT

US$203.2b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Boston Scientific
과거 주가
현재 주가	US$1,808.65
52주 최고치	US$1,808.65
52주 최저치	US$949.03
베타	0.80
11개월 변경	5.71%
3개월 변경 사항	22.62%
1년 변경 사항	92.39%
33년 변화	107.84%
5년 변화	116.73%
IPO 이후 변화	2,066.05%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	BSX *	MX Medical Equipment	MX 마켓
7D	2.1%	0%	0%
1Y	92.4%	0%	0%

수익률 대 산업: BSX * 지난 1년 동안 15.3 %를 반환한 MX Medical Equipment 산업을 초과했습니다.

수익률 대 시장: BSX * 지난 1년 동안 -3.7 %를 반환한 MX 시장을 초과했습니다.

가격 변동성

Is BSX *'s price volatile compared to industry and market?
BSX * volatility
BSX * Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

안정적인 주가: BSX * 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: 지난 1년간 BSX * 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다.

회사 소개

설립	직원	CEO	웹사이트
1979	48,000	Mike Mahoney	www.bostonscientific.com

Boston Scientific Corporation은 전 세계의 다양한 중재 의료 전문 분야에서 사용되는 의료 기기를 개발, 제조 및 판매합니다. 메드서지(MedSurg)와 심혈관 두 부문으로 나뉘어 운영됩니다. 이 회사는 해상도 클립, 담도 스텐트 시스템, 스텐트 및 전기소작술 강화 전달 시스템, 직접 시각화 시스템, 디지털 카테터, 일회용 십이지장 내시경 등 위장 및 폐 질환을 진단하고 치료하는 장치를 제공합니다; 요관 스텐트, 카테터, 바구니, 가이드 와이어, 피복, 풍선, 일회용 디지털 연성 요관경, 홀뮴 레이저 시스템, 인공 요도 괄약근, 레이저 시스템, 섬유 및 하이드로겔 시스템을 포함한 비뇨기과 질환 치료용 기기; 척수 자극기 시스템, 독점 프로그래밍 소프트웨어, 고주파 발생기, 간접 감압 시스템, 연습 최적화 도구, 심부 뇌 자극 시스템 등 신경 운동 장애를 치료하고 만성 통증을 관리하는 장치.

Boston Scientific Corporation 기본 사항 요약

Boston Scientific 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BSX * 기본 통계
시가총액	Mex$2.68t
수익(TTM)	Mex$36.07b
수익(TTM)	Mex$320.08b

74.3x

P/E 비율

8.4x

P/S 비율

BSX * 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BSX * 손익 계산서(TTM)
수익	US$15.91b
수익 비용	US$4.97b
총 이익	US$10.94b
기타 비용	US$9.15b
수익	US$1.79b

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	1.22
총 마진	68.74%
순이익 마진	11.27%
부채/자본 비율	51.9%

BSX * 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BSX * 주식 개요

보상

위험 분석

Boston Scientific Corporation 경쟁사

NYSE:SYK

US$148.2b

NYSE:MDT

US$109.0b

NasdaqGS:ISRG

US$191.9b

NYSE:ABT

US$203.2b

가격 내역 및 성능

최근 뉴스 및 업데이트

Boston Scientific Corporation Announces Positive Three-Year Primary Endpoint Results from the OPTION Global Clinical Trial of the Watchman FLX

BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders.

Now 24% overvalued after recent price rise

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Cortex, Inc. from Ajax Health.

Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire Cortex EP from Ajax Health.

Third quarter 2024 earnings released: EPS: US$0.32 (vs US$0.34 in 3Q 2023)

Recent updates

Boston Scientific Corporation Announces Positive Three-Year Primary Endpoint Results from the OPTION Global Clinical Trial of the Watchman FLX

BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders.

Now 24% overvalued after recent price rise

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Cortex, Inc. from Ajax Health.

Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire Cortex EP from Ajax Health.

Third quarter 2024 earnings released: EPS: US$0.32 (vs US$0.34 in 3Q 2023)

Boston Scientific Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Now 22% overvalued after recent price rise

Boston Scientific Corporation Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System

Boston Scientific Corporation to Report Q3, 2024 Results on Oct 23, 2024

Boston Scientific Corporation Receives Japanese Regulatory Approval for the Farapulse™ Pulsed Field Ablation System

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Silk Road Medical, Inc (NasdaqGS:SILK) from a group of shareholders.

Boston Scientific Corporation Elects David Habiger to Board of Directors

Second quarter 2024 earnings released: EPS: US$0.22 (vs US$0.18 in 2Q 2023)

Boston Scientific Corporation Provides Earnings Guidance for the Third Quarter and Full Year of Fiscal Year 2024

Boston Scientific Corporation to Report Q2, 2024 Results on Jul 24, 2024

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion.

Boston Scientific Corporation Appoints Cheryl Pegus to its Board of Directors

First quarter 2024 earnings released: EPS: US$0.34 (vs US$0.21 in 1Q 2023)

Boston Scientific Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Boston Scientific Corporation to Report Q1, 2024 Results on Apr 24, 2024

New minor risk - Shareholder dilution

Boston Scientific Corporation, Annual General Meeting, May 02, 2024

Full year 2023 earnings released: EPS: US$1.08 (vs US$0.45 in FY 2022)

Boston Scientific Corporation Announces Executive Changes, Effective March 1, 2024

Boston Scientific Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2024

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Boston Scientific Corporation to Report Q4, 2023 Results on Jan 31, 2024

Boston Scientific Corporation Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

Nelda J. Connors and David J. Roux Not to Stand for Re-Election as Members of the Board of Directors of Boston Scientific Corporation

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Relievant Medsystems, Inc.

Boston Scientific Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings released: EPS: US$0.34 (vs US$0.12 in 3Q 2022)

Boston Scientific Corporation Announces Positive 12-Month Results from the Pivotal AGENT IDE Clinical Trial of the AGENT™ Drug-Coated Balloon

Boston Scientific Corporation Provides Earnings Guidance for the Full Year 2023

Boston Scientific Corporation Announces FDA Approval for the Latest-Generation watchMAN FLX Pro Left Atrial Appendage Closure Device

Boston Scientific Corporation to Report Q3, 2023 Results on Oct 26, 2023

Boston Scientific Corporation Announces Positive 12-Month Results from the Pivotal Advanced Clinical Trial of the FARAPULSE™ Pulsed Field Ablation System

Second quarter 2023 earnings released: EPS: US$0.18 (vs US$0.17 in 2Q 2022)

Boston Scientific Corporation Receives FDA Approval for the POLARx™ Cryoablation System

Boston Scientific Corporation (NYSE:BSX) agreed to acquire EV Business and B Braun of Aesculap AG for €47 million.

Boston Scientific Corporation to Report Q2, 2023 Results on Jul 27, 2023

Insufficient new directors

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of an additional stake in M.I.TECH Co.,Ltd (KOSDAQ:A179290) from Synergy Innovation Co., Ltd. (KOSDAQ:A048870)

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Insufficient new directors

Insider recently sold Mex$11m worth of stock

Boston Scientific Corporation Receives FDA Clearance for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System

Full year 2022 earnings released: EPS: US$0.45 (vs US$0.69 in FY 2021)

Boston Scientific Corporation Provides Earnings Guidance for First Quarter of 2023 and Full Year 2023

Boston Scientific Corporation, Annual General Meeting, May 04, 2023

Insufficient new directors

Boston Scientific Corporation to Report Q4, 2022 Results on Feb 01, 2023

Independent Director recently sold Mex$16m worth of stock

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.